Clinical experience with DTPw-HBV and DTPw-HBV/Hib combination vaccines

Abstract

Background: Combined diphtheria-tetanus-whole-cell pertussis (DTPw) vaccines remain the cornerstone of many childhood vaccination programs. Larger DTPw-based combination vaccines facilitate high coverage and protection against other childhood pathogens, such as hepatitis B (HBV) and Haemophilus influenzae type b (Hib). Such vaccines have been available since the mid-1990s (Tritanrix^™-HBV and Tritanrix^™-HBV/Hib; GlaxoSmithKline [GSK] Biologicals), demonstrating excellent immunogenicity in various schedules. In order to address growing demand for DTPw-based vaccines, GSK Biologicals have developed the Zilbrix^™ range using a new DTPw antigen source and containing reduced quantities of polyribosylribitol phosphate [PRP]. Objective: This article presents clinical trial results for both DTPw-based vaccines. Methods: GSK Biologicals provided a comprehensive data package, which was supplemented with a Medline literature search. Conclusion: New antigen sources and reduced PRP will ensure the continued supply of DTPw-based combination vaccines for vital global mass vaccination campaigns.

Keywords::

• combination pediatric vaccines
• diphtheria
• DTPw-HBV/Hib
• Haemophilus influenza type b
• hepatitis B
• tetanus
• whole-cell pertussis